AbbVie oral hep C drugs cure 96 percent in late stage trial
(Reuters) - AbbVie Inc's all-oral hepatitis C therapy cured 96 percent of difficult-to-treat patients in a late-stage clinical trial after 12 weeks, k...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/AkAaZBXgCiU/story01.htm
No comments:
Post a Comment